Friday Satellite Symposia

A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by AstraZeneca Pharmaceuticals LP, and Bristol Myers Squibb.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Sheraton - Napoleon Ballroom AB

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on the role of chimeric antigen receptor (CAR) T-cell therapy in the management of multiple myeloma (MM). Four clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, each faculty member will provide a number of interesting cases of patients with MM receiving treatment with available and investigational CAR T-cell therapies for program development. RTP will select specific deidentified patients for discussion during the activity consistent with the defined educational objectives.

To set the stage for discussion and debate, at the beginning of each of the 4 modules, one of the faculty members will present a case from his/her practice. Each case discussion will attempt to frame a handful of educational issues and allow the faculty to describe how they currently think through the current and potential future role of CAR T-cell therapy for patients with MM. Following the case-based discussion, a faculty member will deliver a presentation reviewing relevant scientific knowledge, available data sets and ongoing research studies related to the topics under review. Audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Sarah M. Larson , MD
UCLA Health Santa Monica Cancer Care
Santa Monica,  CA, United States

Shambavi Richard , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Peter Voorhees , MD
Atrium Health Levine Cancer Institute
Charlotte,  NC, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together

This program is supported by Alexion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Johnson and Johnson.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Hall C

In this 90-minute symposium, some of the foremost experts in light-chain (AL) amyloidosis research and care will share actionable strategies for navigating complex challenges in this rare disease.  

Topics will include:

• Diagnosis, staging, and stratifying: Improving timeliness and accuracy 
• Treatment: Developing personalized, evidence-based plans 
• Patient support: Helping patients navigate the long journey  
• Workflows: Optimizing systems and teamwork 

The event speakers, involved in some of the most consequential trials in AL amyloidosis, will also examine key data for current treatments and novel approaches like fibril targeting. Register now to secure your spot, and prepare your questions for the live Q&A at the end of the session.

Speakers:

Morie Gertz , MD
Mayo Clinic
Rochester,  MN, United States

Suzanne Lentzsch , MD, PhD
Columbia University Medical Center
New York,  NY, United States

Pedro Vianna , MD
Harvard Medical School
Boston,  MA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation

This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Hilton - Grand Ballroom CD

The integration of bispecific T-cell engagers (TCEs) into the management of B-cell acute lymphoblastic leukemia (B-ALL) has transformed modern care, enabling deeper and more durable remissions and establishing measurable residual disease (MRD) as a central guide for treatment decisions. Emerging next-generation CD19 x CD3 bispecifics have demonstrated potent antileukemic activity while reducing cytokine-mediated toxicity, simplifying administration, and broadening the feasibility of off-the-shelf immunotherapy for patients who may not be candidates for CAR-T therapy or who have progressed following prior immune-based treatment. Adapting B-ALL management protocols to reflect the wider use of bispecifics will likely become an important aspect of modern care.

PeerView’s educational symposium will combine real-time assessment of practice patterns with expert presentations and multi-perspective case discussions to reevaluate the role of TCE therapy across B-ALL management, including sequencing strategies utilizing available and emerging bispecifics. Throughout, the expert faculty will provide practical guidance on integrating expanding off-the-shelf immunotherapy options into individualized treatment pathways, including for patients who are or are not eligible for CAR-T.

Chair:

Nicola Goekbuget , MD
University Hospital
Frankfurt,  Germany

Speakers:

Ibrahim Aldoss , MD
City of Hope
Duarte,  United States

Bijal Shah , MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa,  FL, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review - A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Genmab US Inc

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Sheraton - Napoleon Ballroom CD

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on the use of bispecific antibodies in the management of non-Hodgkin lymphoma (NHL). Four leading clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. To support the theme of the activity, leading up to the symposium, RTP will recruit 2 additional investigators who will participate in a one-on-one interview with Dr Neil Love during which they will present challenging cases from their practices of patients with NHL treated or considered for treatment with bispecific antibodies for which they sought out input or a second opinion from a colleague. Excerpts from each interview will be selected for presentation during the symposium in accordance with the defined educational objectives.

The agenda for the event, which will be divided into 4 topic modules, will feature case-based discussions set up by the video excerpts followed by faculty led presentations reviewing recent data sets, current management approaches and ongoing trials. To promote audience engagement, audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Nancy L Bartlett , MD
Washington University School of Medicine in St Louis
St Louis,  United States

Chan Cheah , MD, PhD
The University of Western Australia
Perth,  Australia

Lorenzo Falchi , MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum

This program is supported by an educational grant from Genmab. This activity is provided by PRIME Education. There is no fee to participate.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - R02-R05

CD20 × CD3 bispecific antibodies (bsAbs) are reshaping the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), while introducing new clinical and operational challenges. Clinicians must make informed decisions around patient selection, sequencing alongside CAR T-cell therapy and other novel agents, outpatient initiation, toxicity monitoring, and care coordination across settings. This interactive, case-based program is designed to close the gap between evidence and execution by translating the latest clinical data and guideline updates into practical, real-world strategies. Through real-time polling, clinical decision checkpoints, and faculty-led discussion, learners will apply evidence in context and refine their clinical approach. 

Using real-world cases in DLBCL and FL, participants will build skills in selecting and sequencing bsAbs, implementing step-up dosing and outpatient workflows, and anticipating and managing toxicities such as CRS, ICANS, cytopenias, and infections. With a focus on practical implementation, the program addresses common barriers including staffing, infrastructure, and referral processes. Additionally, faculty will introduce the NHL BsAb Navigator, a point-of-care tool to support consistent integration of bsAbs into practice. Attendees will leave with actionable frameworks and workflow solutions to enhance care coordination, improve efficiency, and expand access to these therapies.

Speakers:

Jennifer L. Crombie , MD
Dana Farber Cancer Institute
Boston,  MA, United States

Yasmin H Karimi , MD
University of Michigan
Ann Arbor,  MI, United States

Shelby Sullivan , PharmD
PRIME Education, LLC
New York,  NY, United States

Managing Company Contact

Eryn Litvinas , PRIME Education, LLC
Email: [email protected]

---

CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation

This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 208-210

Join Decera Clinical Education for an engaging Master Class symposium exploring the latest advancements in CAR T-cell therapy for relapsed/refractory (R/R) lymphomas. This dynamic event features expert-led small group discussions, real-world case challenges, and interactive polling to examine the role of CAR T-cell therapies across B-cell lymphoma subtypes. Gain practical insights into patient selection, referral pathways, and coordination of care, along with strategies to manage acute and chronic toxicities such as CRS and ICANS. Learn how to educate patients and caregivers, implement survivorship planning, and optimize long-term outcomes. The symposium also highlights next-generation CAR T-cell innovations, including off-the-shelf products and combination strategies. Engage directly with faculty during live Q&A sessions, apply knowledge through interactive cases, and leave equipped to enhance care for patients receiving CAR T-cell therapy.

Chair:

Michael R. Bishop , MD
University of Chicago
Chicago,  IL, United States

Speakers:

Jeremy S. Abramson , MD
Harvard Medical School
Cambridge,  MA, United States

Caron Jacobson , MD
Harvard Medical School
Cambridge,  MA, United States

Michael D. Jain , MD, PhD
Moffitt Cancer Center
Tampa,  FL, United States

Tanya Siddiqi , MD
City of Hope
Irvine,  CA, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies

This program is supported by educational grants from AbbVie and Menarini Stemline.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - La Nouvelle A-B

Blastic plasmacytoid dendritic cell neoplasm is a rare, aggressive hematologic malignancy in which diagnostic delay and treatment uncertainty remain common because features overlap with cutaneous lymphomas, acute leukemias, and other myeloid neoplasms. The therapeutic landscape is expanding rapidly, with the only approved CD123-directed cytotoxin, an investigational CD123-directed antibody-drug conjugate under FDA review, and additional bispecifics, CAR T-cell platforms, and combination regimens advancing through development. This case-based session pairs interactive case discussion with focused didactic data to enable clinicians to apply current diagnostic criteria, interpret evolving evidence across frontline and relapsed/refractory settings, manage capillary leak syndrome and class-specific toxicities, and coordinate multidisciplinary care that incorporates transplant evaluation and clinical trial access across academic and community practice.

Chair:

Naveen Pemmaraju , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Andrew A. Lane , MD, PhD
Dana-Farber Cancer Institute
Boston,  MA, United States

Gary J. Schiller , MD
David Geffen School of Medicine at UCLA
Los Angeles,  CA, United States

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies

This program is supported by AstraZeneca, BeOne Medicines, and Lilly. Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 243-245

This engaging symposium will explore how shared decision-making, patient priorities, and rapidly evolving evidence can guide more individualized treatment selection and sequencing for patients with CLL/SLL. Developed by Decera Clinical Education in partnership with the CLL Society, the session will address persistent gaps in patient engagement, biomarker testing, and the practical integration of established and emerging targeted therapies. Through evidence-based challenges, interactive polling, and expert discussion, the program will examine how clinicians can better align treatment choices with patient goals, disease biology, current guideline recommendations, and new clinical data. Key themes include improving communication around treatment options, applying biomarker and resistance testing, selecting among fixed-duration and continuous regimens, and evaluating the roles of covalent and noncovalent BTK inhibitors, BCL-2 inhibitor–based combinations, BTK degraders, and cellular therapy. The overall purpose is to translate current and emerging evidence into patient-centered strategies that support equitable, informed, and preference-sensitive CLL/SLL care across frontline and relapsed/refractory settings.

Chair:

Nitin Jain , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Brian Koffman , MD
CLL Society
Claremont,  United States

Meghan C. Thompson , MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Jennifer A. Woyach , MD
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life

This program is supported by Novartis Pharmaceuticals Corporation

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Great Hall BC

Join three leading CML experts for a high-impact, 90-minute live symposium focused on the latest strategies to optimize chronic myeloid leukemia therapy. This engaging, data-driven discussion will help clinicians sharpen treatment decisions across the CML continuum—from selecting the most appropriate first-line TKI to navigating molecular failure, resistance, and long-term sequencing. Faculty will also discuss practical strategies to manage chronic toxicities and support treatment-free remission eligibility, along with a look at promising pipeline agents that may shape the future of CML care. Designed to deliver immediately actionable insights, this program will equip physicians with the knowledge and confidence to make more precise, personalized treatment decisions and improve outcomes for patients living with CML.

Chair:

Ehab Atallah , MD
Medical College of Wisconsin
Milwaukee,  WI, United States

Speakers:

Michael Mauro , MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Kendra L. Sweet , MD
Moffitt Cancer Center
Tampa,  FL, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making

This program is supported by Servier Pharmaceuticals, LLC.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 343-345

This symposium focuses on optimizing personalized treatment strategies in acute myeloid leukemia (AML) through effective integration of molecular testing and targeted therapies. As treatment options expand to include agents targeting IDH1, IDH2, and FLT3 mutations, clinicians must navigate increasingly complex decision-making processes, particularly for older patients or patients who are not candidates for intensive therapy. The purpose of the session is to equip clinicians with practical, evidence-based approaches to when and how to perform molecular testing, interpret results, and apply findings to individualized treatment selection. Emphasis will be placed on bridging gaps between guideline recommendations and real-world practice, especially in community settings where barriers to timely testing and interpretation may persist. The live format enables expert discussion, case-based learning, real-time polling, and faculty-audience interaction through a live Q&A, supporting active application of knowledge. By engaging the audience in clinical scenarios and decision-making exercises, the session aims to improve confidence, consistency, and competency in managing patients with molecularly defined AML.

Chair:

Richard Stone , MD
Dana Farber Cancer Insitute
Boston,  MA, United States

Speakers:

Uma Borate , MD, MSc
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Curtis Lachowiez , MD
OHSU Knight Cancer Institute
Portland,  United States

Managing Company Contact

Alison McMorrow , Paradigm Medical Communications, LLC
Email: [email protected]

---

Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care

This program is supported by the Roswell Park Alliance Foundation. Other support is currently pending.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 343-345

Rapid advances in immune-based therapies for multiple myeloma have created meaningful gaps in clinician knowledge, treatment decision making, and care coordination, particularly for patients with relapsed or refractory disease. This activity aims to improve evidence-based care, coordination across treatment settings and outcomes for patients with multiple myeloma

Chair:

Marco Davila , MD, PhD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY, United States

Managing Company Contact

Ashley Snowden , Roswell Park Comprehensive Cancer Center
Email: [email protected]

---

Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease

This program is supported by Blueprint Medicines, a Sanofi company. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 265-268

Join Decera Clinical Education for an interactive symposium focused on improving timely diagnosis, risk stratification, and patient-centered management of systemic mastocytosis across indolent and advanced disease. This engaging program will translate evolving diagnostic standards and therapeutic evidence into practical, clinic-ready workflows, with emphasis on applying ICC/WHO criteria, interpreting bone marrow findings, serum tryptase, KIT D816V testing, and immunophenotyping, and recognizing the multisystem manifestations of disease.

Through a team-based trivia format, case-driven discussion, real-time polling, and expert roundtable dialogue, the session will address common barriers that contribute to delayed diagnosis, misclassification, and inconsistent care. Key themes include distinguishing indolent from advanced systemic mastocytosis, assessing symptom burden and organ involvement, preventing and managing anaphylaxis, and selecting appropriate supportive, cytoreductive, KIT-targeted, or investigational treatment strategies. The overall purpose is to equip clinicians with actionable approaches to align therapy with disease subtype, patient goals, safety considerations, and longitudinal quality-of-life needs while strengthening multidisciplinary coordination across the care continuum.

Chair:

Daniel J DeAngelo , MD, PhD
Harvard Medical School
Boston,  MA, United States

Speakers:

Brian Chernak , MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

James K. McCloskey , MD
HMH John Theurer Cancer Center Lymphoma Hackensack
Hackensack,  United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care

This program is supported by educational grants from Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, and Taiho Oncology, Inc.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Great Hall AD

This activity employs a Medical Crossfire® format, a signature debate-style educational design that pairs short, focused didactic presentations with dynamic, moderated panel discussions. The program brings together four clinical experts to review the latest data regarding the management of patients with AML. These recorded questions are incorporated throughout the activity to address real-world challenges, uncertainties, and decision points encountered in routine care. Following each didactic segment, faculty engage in moderated panel discussions that respond directly to these clinical questions, providing expert interpretation and context while encouraging dynamic exchange. This approach ensures that the educational content remains grounded in the lived experiences of community oncologists, promotes bidirectional learning, and enhances the relevance and applicability of emerging data in AML management.

Chair:

Naval Daver , MD
MD Anderson Cancer Center
Houston, TX,  United States

Speakers:

Richard Dillon , MD
King's College London
London,  United Kingdom

Gail J Roboz , MD
Weill Cornell Medicine
New York,  NY, United States

Amer M. Zeidan , MD, MBBS
Yale Cancer Center
Connecticut,  United States

Managing Company Contact

Kelly McGregor
Email: [email protected]

---

Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum

This program is supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - La Nouvelle C

The treatment of diffuse large B-cell lymphoma is shifting rapidly from a single chemoimmunotherapy backbone toward a more biology-informed, mechanism-driven model of care. Routine integration of immunohistochemistry, gene expression profiling, and next-generation sequencing has redefined how clinicians classify disease, estimate prognosis, and select frontline therapy. Newly approved and emerging frontline regimens — including polatuzumab vedotin-based chemoimmunotherapy, Bruton tyrosine kinase inhibitor combinations, bispecific antibodies, and CAR T-cell strategies — expand options across germinal center, activated B-cell, and high-risk genomic subtypes. This session uses a debate-style design that pairs focused didactic content with moderated panel discussions, allowing expert clinicians to examine evolving evidence on molecular testing, frontline regimen selection, and treatment sequencing across the disease continuum.

Speakers:

Lori Leslie , MD
Hackensack University Medical Center
Hackensack,  NJ, United States

Matthew A. Lunning , DO
University of Nebraska Medical Center
Omaha,  NE, United States

Jason Westin , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies

This program is supported by an educational grant from Sanofi Genzyme.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 393-396

The therapeutic landscape of newly diagnosed multiple myeloma has been transformed over the past several years, with anti-CD38 monoclonal antibody-based quadruplet regimens emerging as the guideline-preferred frontline standard for transplant-eligible patients and a growing option for selected non-transplant candidates. Emerging data on subcutaneous and on-body anti-CD38 delivery, response-adapted maintenance, and the integration of measurable residual disease as a treatment decision tool have introduced new complexity into individualized treatment planning. Frontline strategies involving CAR-T cell therapy, bispecific antibodies, antibody-drug conjugates, and cereblon E3 ligase modulators are advancing rapidly in pivotal trials. This satellite symposium employs a debate-style educational design that pairs focused didactic content with moderated panel discussions, allowing four expert clinicians to examine evolving evidence and articulate differing perspectives on quadruplet therapy selection, MRD-guided treatment decisions, and the management of treatment-related adverse events across transplant-eligible and -ineligible populations. Attendees will leave better prepared to apply current evidence to personalized, risk-adapted frontline treatment plans and to monitor and manage emerging toxicities associated with novel combination regimens.

Speakers:

Rahul Banerjee , MD
Fred Hutchinson Cancer Center
Seattle,  WA, United States

Jesús G. Berdeja , MD
Tennessee Oncology
Nashville,  TN, United States

Krina K. Patel , MD, MSc
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies

This program is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
Hilton - Grand Ballroom AB

New science is driving a clinical realignment in mantle cell lymphoma (MCL) care, leading to more personalized use of targeted therapies and modernized sequential treatment. In newly diagnosed MCL, the addition of covalent Bruton's tyrosine kinase inhibitors (cBTKi) to chemoimmunotherapy and the emergence of chemotherapy-free regimens have improved outcomes for patients and established new standards of care. Non-covalent BTK inhibitors (ncBTKi), new BCL2 inhibitors (BCL2i), and CAR-T cell therapy offer effective options for addressing resistance and aggressive or high-risk relapse after progression on cBTKi.

This Seminars & Workshop live symposium will combine the teaching power of real-world cases with the latest scientific evidence to enhance clinical decision-making across MCL disease settings. Our expert faculty will clarify the evidence supporting cBTKi-based combinations; interpret data on sequential approaches with ncBTKi, BCL2i, and CAR-T therapy; and provide insights on the integration of targeted and immunotherapy options across frontline and relapsed settings.

Chair:

Prof. Dr. Martin Dreyling , MD, PhD
LMU University Hospital
Munich,  Germany

Speakers:

Kami Maddocks , MD
The Ohio State University Comprehensive Cancer Center
Columbus,  OH, United States

Christine Ryan , MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera

This program is supported by by an educational grant from PharmaEssentia.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - R06-R09

Polycythemia vera and essential thrombocythemia are chronic myeloproliferative neoplasms driven by constitutive JAK/STAT pathway activation. These diseases carry significant thrombotic risk, burdensome disease-related symptoms, and the potential for progression to myelofibrosis or acute leukemia. Recent therapeutic advances — including the 2024 FDA approval of ropeginterferon alfa-2b for polycythemia vera, the phase 3 VERIFY readout of rusfertide in phlebotomy-dependent polycythemia vera, the SURPASS-ET superiority data for ropeginterferon alfa-2b versus anagrelide in essential thrombocythemia, and emerging activity from LSD1 inhibitors and other novel agents — have meaningfully expanded the treatment armamentarium and complicated treatment selection.

This Cases and Conversations satellite symposium uses sequential patient cases and moderated faculty panel discussions to examine current and emerging treatment strategies across risk-stratified polycythemia vera and essential thrombocythemia, with focused attention on hydroxyurea resistance and intolerance, interferon-based therapy, JAK inhibitor positioning, and the management of treatment-related adverse events that affect long-term adherence and outcomes.

Chair:

Marina Kremyanskaya , MD, PhD
Icahn School of Medicine at Mount Sinai
New York,  NY, United States

Speakers:

Patrick Harrington , MD
Guys and St Thomas’ Hospital
London,  United Kingdom

Francesca Palandri , MD, PhD
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia 'Seràgnoli'
Bologna,  Italy

Pankit Vachhani , MD
University of Alabama at Birmingham
Birmingham,  NY, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care

This program is supported by an independent educational grant from Bristol Myers Squibb.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - 217-219

This 90-minute Friday Satellite Symposium, preceding the 68th ASH Annual Meeting and Exposition, explores how cereblon E3 ligase modulators (CELMoDs) are redefining treatment strategies for relapsed/refractory multiple myeloma. Expert faculty review the biologic rationale and immunologic effects of CELMoDs, examine pivotal clinical data supporting emerging combination regimens, and discuss how these agents can be sequenced alongside T-cell–redirecting therapies. The symposium also provides practical guidance on managing hematologic toxicities associated with CELMoDs, including neutropenia monitoring and dose modifications to maintain treatment intensity. Finally, participants will learn how serial minimal residual disease assessment can be incorporated into treatment decisions to optimize therapy duration, response assessment, and long-term patient outcomes.

Chair:

Paul G. G. Richardson , MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

James Richard Berenson , MD
Berenson Cancer Center
West Hollywood,  CA, United States

Luciano J. Costa , MD, PhD
University of Alabama at Birmingham
Birmingham,  AL, United States

Managing Company Contact

Andrea Mathis , Global Learning Collaborative
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice

This program is supported by Sanofi.

Friday, December 11, 2026
11:00 a.m. - 2:00 p.m. Central time
MCCNO - Hall B2

Elevate your clinical practice by attending this high-impact, 90-minute symposium featuring renowned multiple myeloma (MM) experts Dr C. Ola Landgren, Dr Sikander Ailawadhi, and Dr Noopur Raje. As the first-line treatment landscape for MM rapidly evolves, translating complex clinical trial data into actionable, community-based care plans is more critical than ever. This interactive session bridges that gap by demonstrating how to confidently deploy high-potency, multi-mechanism induction regimens tailored to your patients' unique clinical profiles.

Through a collaborative, interprofessional lens, our expert panel will guide you through objective frailty stratifications, proactive dose-adaptation strategies that preserve quality of life, and the logistics of integrating novel drug delivery formulations into everyday clinic workflows. Do not miss this essential opportunity to master shared decision-making, optimize upfront treatment intensity, and redefine what is possible for your patients from cycle 1.

Speakers:

Sikander Ailawadhi , MD
Mayo Clinic Comprehensive Cancer Center
Jacksonville,  FL, United States

Noopur Raje , MD
Mass General Brigham Cancer Institute
Boston,  MA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going - A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by GSK and Bristol Myers Squibb.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Sheraton - Napoleon Ballroom CD

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — will focus on myelofibrosis (MF). Five clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, each faculty member will provide a number of interesting cases of patients with MF for program development. RTP will select specific deidentified patients for discussion during the activity consistent with the defined educational objectives. To set the stage for discussion and debate, at the beginning of each of the 5 modules, one of the faculty members will present a case from his/her practice. Each case discussion will attempt to frame a handful of educational issues and allow the faculty to describe how they currently think through the treatment and management of patients with MF. Following the case-based discussion, a faculty member will deliver a presentation reviewing relevant scientific knowledge, available data sets and ongoing research studies related to the topics under review. Audience members will have the opportunity to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Lucia Masarova , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Ruben Mesa , MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Charlotte,  NC, United States

Francesco Passamonti , MD
University of Milan
Milan,  Italy

Raajit K. Rampal , MD, PhD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Acknowledging the Rare: Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders

This program is supported by Recordati Rare Diseases.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Hall B2

This 90-minute live symposium is designed to address the diagnostic and therapeutic complexities of three rare hematologic conditions: Idiopathic Multicentric Castleman Disease (iMCD), Cold Agglutinin Disease (CAD), and Immune Thrombocytopenia (ITP). The program features distinct disease segments with expert faculty, which will specifically focus on overcoming key challenges, such as minimizing diagnostic delays, achieving evidence-based, data-driven treatment selection, and reducing treatment burden for patients. Audience response polling questions will be integrated for interactive discussion. 

Chair:

Srikanth Nagalla , MBBS, MS
Miami Cancer Institute
Miami,  FL, United States

Speakers:

Howard A Liebman , MD, MA
University of Southern California
Los Angeles,  CA, United States

Frits van Rhee , MD
University of Arkansas for Medical Sciences
Little Rock,  United States

Ilene Weitz , MD
University of Southern California
Los Angeles,  CA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

---

Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms

This program is supported by educational grants from Geron Corporation, GSK, and PharmaEssentia.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - R06-R09

The therapeutic landscape of myeloproliferative neoplasms has evolved rapidly, with new JAK inhibitors, novel targeted agents, and disease-modifying strategies reshaping how clinicians manage myelofibrosis, polycythemia vera, and essential thrombocythemia. Recent pivotal trial readouts for hepcidin mimetics, BET inhibitors, MDM2 inhibitors, LSD1 inhibitors, telomerase inhibitors, calreticulin-targeted antibodies, and novel interferons have expanded options while complicating risk stratification, sequencing, and toxicity management.

This satellite symposium employs an interactive, case-based educational design that integrates didactic data summaries with moderated faculty panel discussions of complex patient scenarios across the MPN continuum. Four expert clinicians will examine emerging evidence, surface real-world decision points, and articulate practical perspectives on therapy selection in myelofibrosis, treatment intensification in polycythemia vera, and risk-adapted management of essential thrombocythemia. The format emphasizes peer exchange, audience response–driven discussion, and integration of evolving evidence into routine practice. Attendees will leave better prepared to apply guideline-aligned risk stratification, evaluate emerging clinical trial data across lines of therapy, and proactively monitor and manage treatment-related adverse events associated with both established and novel agents in MPN care.

Speaker:

Jennifer O'Sullivan , MB Bch BAO
Guy’s and St Thomas’ NHS Foundation Trust
London,  United Kingdom

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation. This activity is provided by PRIME Education. There is no fee to participate.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - R02-R05

As CAR T-cell therapy becomes increasingly integrated into the management of relapsed/refractory NHL, clinicians face growing challenges related to patient selection, referral timing, treatment sequencing, toxicity management, and care coordination across practice settings. Join this case-based, implementation-focused program designed to help clinicians apply the latest CAR T-cell evidence across the entire NHL care continuum. Through real-time polling, clinical decision checkpoints, multidisciplinary discussion, and faculty-guided case applications, alongside a real-world patient vignette sharing insights from the CAR T-cell experience,  attendees will learn how to identify appropriate patients earlier, optimize referral timing, navigate sequencing decisions, implement evidence-based bridging strategies, and manage CRS and ICANS with greater confidence.

Distinct from traditional didactic sessions, this symposium emphasizes actionable workflow solutions and coordinated care models that participants can immediately integrate into practice. Faculty will introduce the NHL CAR T-Cell Navigator, a practical point-of-care resource developed to support referral readiness, toxicity management, shared-care coordination, patient education, and operational consistency across practice settings. Don’t miss your opportunity to gain practical tools, evidence-based strategies, and real-world insights to improve CAR T-cell delivery, streamline multidisciplinary care, and expand access for patients with R/R DLBCL and FL.

Chair:

Peter Riedell , MD
University of Chicago
Chicago,  IL, United States

Speakers:

Daniel J Landsburg , MD
University of Pennsylvania
Philadelphia,  PA, United States

Shelby Sullivan , PharmD
PRIME Education, LLC
New York,  NY, United States

Managing Company Contact

Eryn Litvinas , PRIME Education, LLC
Email: [email protected]

---

FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment

This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, HealthTree Foundation for Chronic Lymphocytic Leukemia.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Hilton - Grand Ballroom CD

The rapid expansion of targeted therapies has transformed the treatment of chronic lymphocytic leukemia (CLL), and is now centered on the use of continuous BTK inhibitor (BTKi) therapy, time-limited BCL2 inhibitor (BCL2i) regimens, and newer finite BTK-BCL2i combinations. Fixed-duration and MRD-guided BTKi-BCL2i combinations that incorporate more selective, second-generation BTKi options are raising expectations for deeper and more durable responses with improved tolerability and safety profiles. Incorporation of targeted, time-limited strategies within first-line care is now informed by patient preferences, high-risk features, goals of therapy, and retreatment potential, alongside logistical, dosing, and safety considerations.

Developed in collaboration with the HealthTree Foundation for CLL, this PeerView Live TownHall symposium will emulate the interactive environment of a town hall meeting that incorporates learner questions to drive dynamic Q&A discussions, realistic case scenarios, and focused expert presentations. Key topics will include the latest evidence and guideline recommendations supporting time-limited BTKi-BCL2i combinations, development of personalized finite therapy protocols, and practical guidance on implementing time-limited approaches in real-world practice.

Chair:

Matthew S Davids , MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Speakers:

Nicole Lamanna , MD
New York-Presbyterian/Columbia University Medical Center
New York,  NY, United States

Lydia Scarfò , MD
Università Vita-Salute San Raffaele
Milan,  Italy

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Hemophilia at the Crossroads: New Evidence for Individualized Care

This program is supported by Sanofi.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Great Hall BC

This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia.

Chair:

Steven Pipe , MD
University of Michigan
Ann Arbor,  MI, United States

Speakers:

Maissaa Janbain , MD
Louisiana Center for Bleeding and Clotting Disorders
New Orleans,  LA, United States

Allison P. Wheeler , MD
Washington Center for Bleeding Disorders
Seattle,  WA, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care

This program is supported by Sanofi.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 217-219

Your patients with immune thrombocytopenia purpura (ITP)  deserve precision care — and this is where the conversation happens. This live symposium leverages real-world case studies and the latest advances in ITP pathophysiology to help you personalize treatment for even your most challenging patients, whether newly diagnosed, refractory, elderly, or at elevated thrombotic risk. You'll explore new and emerging therapies, unpack the key pathophysiology driving smarter treatment selection, and walk away with actionable frameworks to optimize patient outcomes.

ITP is so much more than a platelet count. We'll go beyond the numbers to address the full disease burden — including fatigue, cognitive impairment, heavy menstrual bleeding, and health-related quality of life — and show you how to integrate these critical considerations into shared decision-making with your patients and care team.

Join colleagues for an engaging, case-based experience designed to close knowledge gaps and elevate your practice. Come ready to think, discuss, and leave better equipped to champion the patients who need it most.

Chair:

Sandhya Panch , MD
Fred Hutchinson Cancer Center
Seattle,  WA, United States

Speakers:

Hanny Al-Samkari , MD
Harvard Medical School
Boston,  MA, United States

Gerald A Soff , MD
University of Miamo Health System
Miami,  FL, United States

Managing Company Contact

George Vuturo , AffinityCE
Email: [email protected]

---

Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors

This program is supported by educational grants from Janssen and Kura Oncology.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 393-396

Menin inhibition has rapidly evolved from a preclinical hypothesis to an FDA-approved therapeutic class with activity in molecularly defined subsets of acute myeloid leukemia. Two agents are now approved for relapsed/refractory disease in patients with NPM1 mutations or KMT2A rearrangements, with multiple combination regimens advancing in the relapsed/refractory and frontline settings. Yet the speed of development has outpaced clinical experience, leaving open questions on patient selection, treatment sequencing, response assessment, resistance, and proactive management of class-specific toxicities including differentiation syndrome and QTc prolongation. This satellite symposium uses a gamified hot seat design that places four expert clinicians in real time on case-based decision points, with audience polling on both the preferred treatment approach and the faculty member best positioned to defend it. Brief didactic segments anchor the latest efficacy and safety data for approved and investigational menin inhibitors, including monotherapy and combination strategies with venetoclax, hypomethylating agents, intensive induction backbones, and FLT3 inhibitors. Attendees will leave better prepared to identify candidates for menin inhibitor therapy, integrate emerging combination data into individualized care plans, anticipate and mitigate class-specific toxicities, and recognize early signals of resistance.

Chair:

Eunice Sue Wang , MD
Roswell Park Comprehensive Cancer Center
Buffalo,  NY, United States

Speakers:

Jessica K. Altman , MD
Northwestern University
Chicago,  IL, United States

Aditi Shastri , MD
Montefiore Einstein Comprehensive Cancer Center
Bronx,  NY, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies

This program is supported by an educational grant from Deciphera Pharmaceuticals.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - La Nouvelle C

Primary central nervous system lymphoma is a rare and aggressive extranodal lymphoma confined to the brain, leptomeninges, spinal cord, and eyes, with persistent heterogeneity in frontline management, evolving molecular insights, and a rapidly expanding portfolio of targeted agents for relapsed and refractory disease. High-dose methotrexate–based induction, consolidation choices between autologous stem cell transplant and whole-brain radiotherapy, and integration of MYD88/CD79B-directed and IRAK4-directed strategies have introduced new clinical decision points that often outpace routine practice. This satellite symposium employs a case-based tumor board design that pairs concise didactic framing with moderated faculty discussion across three realistic clinical scenarios, allowing four expert clinicians to examine evolving evidence and articulate differing perspectives on induction optimization, molecular interpretation, and sequencing of emerging targeted therapies. Attendees will leave better prepared to apply evidence-based induction and consolidation strategies, interpret PCNSL-specific molecular alterations and pharmacology, and integrate emerging targeted agents with proactive toxicity monitoring across the disease continuum.

Speakers:

Christopher D'Angelo , MD
University of Nebraska Medical Center
Omaha,  NE, United States

Christian Grommes , MD
Memorial Sloan Kettering Cancer Center
New York,  NY, United States

Ashley Sumrall , MD, FACP, FASCO
Advocate Health
Charlotte,  NC, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

MDS in the Modern Era: Getting Ahead of the 8-Ball

This program is supported by Bristol Myers Squibb, Geron Corporation, and OrcaBio.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - Hall C

This 90-minute symposium will explore the management of myelodysplastic syndromes (MDS) across the disease continuum, highlighting the present paradigm shift from reactive supportive care to proactive early intervention with disease-modifying therapies. The expert faculty will begin with a review of molecular biomarkers and prognostic scoring systems that inform diagnosis and guide therapy selection.

Through case-based discussion, they will first focus on novel strategies to achieve durable transfusion independence and improve survival outcomes by initiating targeted therapies early in the course of lower-risk MDS. The discussion on higher-risk MDS will address selection and sequencing of hypomethylating agents, including oral and intravenous formulations, and the role of targeted therapies in refractory settings. Faculty will then explore recent progress in allogeneic hematopoietic cell transplantation for MDS, including the role of precision-engineered graft options for expanding eligibility and improving outcomes in older and frailer populations. Discussions will highlight the role of interprofessional care teams in monitoring symptom and treatment burden, managing toxicities and barriers to adherence, and coordinating transfusion and transplant care.

The session will conclude with a review of forthcoming clinical data and key takeaways to help clinicians integrate recent evidence into individualized management plans.

Chair:

Guillermo Garcia-Manero , MD
University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Caspian Oliai , MD
University of California Los Angeles
Los Angeles,  CA, United States

David Sallman , MD
Moffitt Cancer Center
Tampa,  FL, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era

This program is supported by educational grants from Amgen, Autolus Therapeutics, and Jazz Pharmaceuticals.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - La Nouvelle A-B

The therapeutic landscape of acute lymphoblastic leukemia has been transformed by bispecific T-cell engagers, antibody-drug conjugates, CAR T-cell therapies, next-generation tyrosine kinase inhibitors, menin inhibitors, and recombinant asparaginase formulations. These advances have improved outcomes across Ph-positive, Ph-negative, pediatric, adolescent and young adult, and older adult populations, while complicating decisions around induction, consolidation, and salvage sequencing. The growing role of high-sensitivity measurable residual disease testing adds further nuance. This session employs a debate-style design that pairs concise didactic content with moderated panel discussions, allowing experts to examine evolving evidence and articulate differing perspectives on frontline therapy, salvage sequencing, CAR T-cell deployment, asparaginase management, and MRD-directed care. Attendees will be better prepared to apply guideline-aligned strategies and to anticipate and manage treatment-related toxicities.

Chair:

Hagop Kantarjian , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Sumit Gupta , MD, PhD
The Hospital for Sick Children
Toronto,  ON, Canada

Elias Jabbour , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Aaron C. Logan , MD, PhD, MPhil
University of California, San Francisco
San Francisco,  CA, United States

Claire Roddie , MD, PhD
University College London (UCL Cancer Institute)
London,  United Kingdom

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice

This program is supported by AstraZeneca, Johnson and Johnson, and Sanofi Genzyme. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 243-245

Join Decera Clinical Education and NCCN for an interactive symposium focused on applying updated evidence and guideline-based strategies to multiple myeloma management across the disease continuum. This program will examine practical decision points from smoldering myeloma and newly diagnosed disease through first relapse and heavily pretreated relapsed/refractory multiple myeloma. Through case challenges, rapid-fire knowledge checks, expert discussion, and audience-driven questions, the session will translate evolving clinical data into individualized treatment approaches that account for disease risk, cytogenetics, transplant eligibility, age, fitness, comorbidities, prior therapy, patient preferences, and access considerations. Key themes include risk stratification and treatment initiation in smoldering myeloma, selection of triplet and quadruplet regimens in newly diagnosed disease, use of measurable residual disease and maintenance strategies, sequencing of novel therapies at relapse, and integration of CAR T-cell therapy, bispecific antibodies, antibody–drug conjugates, CELMoDs, SINE inhibitors, and subcutaneous formulations. The overall purpose is to strengthen equitable, patient-centered, evidence-based care while addressing real-world barriers to optimal treatment, toxicity management, clinical trial access, and guideline implementation.

Chair:

Carol Huff , MD
Johns Hopkins University
Baltimore,  MD, United States

Speaker:

Larry D Anderson Jr , MD, PhD
UT Southwestern Medical Center
Dallas,  TX, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

---

Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions

This program is supported by AstraZeneca and Genmab. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 265-268

Join Decera Clinical Education for an interactive symposium examining how bispecific antibody–based therapies are reshaping treatment for follicular lymphoma and diffuse large B-cell lymphoma. This program will explore clinically meaningful differences among established and emerging bispecific antibodies, including mechanisms of action, structural characteristics, dosing considerations, safety profiles, and implications for individualized treatment sequencing.

Through concise evidence updates, rapid-insights polling, interactive cases, and real-world community challenges, the session will translate recent and emerging data into practical strategies for selecting appropriate patients, integrating bispecific antibody–based regimens across the disease course, and identifying candidates for clinical trials. Key themes include optimizing therapy in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, anticipating how evolving evidence may change future treatment algorithms, and addressing operational considerations such as step-up dosing, outpatient vs inpatient administration, adverse event monitoring, CRS and neurotoxicity management, infection risk, patient education, and care coordination. The overall purpose is to equip clinicians to confidently and safely incorporate bispecific antibody–based therapies into lymphoma care across community and specialist settings.

Chair:

Matthew Matasar , MD, MS
Rutgers Cancer Institute
New Brunswick,  NJ, United States

Speaker:

Tycel Phillips , MD
Rutgers Cancer Institute
New Brunswick,  NJ, United States

Managing Company Contact

Ishana Fleurant , Decera Clinical
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence

This program is supported by an educational grant from Sanofi. This activity is provided by Answers in CME.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
MCCNO - 208-210

Anti-CD38–based quadruplet regimens are rapidly reshaping frontline treatment for newly diagnosed multiple myeloma (NDMM). In this interactive 60-minute symposium, two leading multiple myeloma experts will explore how to turn these evolving updates—alongside advances in minimal residual disease (MRD) testing, transplant criteria, and treatment delivery—into practical, personalized treatment strategies.  Through real-world insights and expert discussion, they will examine how to move beyond a “one-size-fits-all” approach to optimize frontline patient care in everyday practice. 

Get up to speed on the rapidly changing NDMM treatment landscape and leave with practical insights you can apply immediately in clinical practice.

Don’t miss the live Q&A, where faculty will address real-world questions and help refine your approach to NDMM management.

Speakers:

Amrita Krishnan , MD
Director of Judy and Bernard Briskin Center for Multiple Myeloma
Irvine,  CA, United States

Adriana Rossi , MD, MSc
Icahn School of Medicine, Mount Sinai Hospital
New York,  NY, United States

Managing Company Contact

Kaitlyn Bell , No affiliations
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care

This program is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Friday, December 11, 2026
3:00 p.m. - 6:00 p.m. Central time
Hilton - Grand Ballroom AB

The rapid rise of bispecific antibodies has reshaped patient care for non-Hodgkin lymphoma (NHL) and established off-the-shelf immunotherapy as a central treatment component in DLBCL and follicular lymphoma. First validated in later-line settings, CD20 x CD3 bispecifics have shown strong efficacy, practical advantages, and manageable safety, enabling outpatient community use through step-up dosing and proven toxicity mitigation strategies. Growing evidence now supports their move into earlier lines of treatment, while next-generation CD20 x CD3 options and low-affinity CD19 x CD3 platforms are set to further expand the role of immunotherapy in NHL.

PeerView's MasterClass & Case Forum will provide concise, evidence-based instruction paired with real-world case discussions on integrating bispecific antibodies into NHL management. Experts will review evidence and guidelines for bispecific monotherapy and combination strategies, including treatment selection and sequencing; dosing formulations and administration approaches; and best practices for managing toxicities such as CRS, ICANS, and infections.

Chair:

Prof. Dr. Max Topp , MD
Universitätsklinikum Würzburg
Würzburg,  Germany

Speakers:

Elizabeth Brem , MD
University of California, Irvine
Orange,  CA, United States

Sameh Gaballa , MD
H. Lee Moffitt Cancer Center
Tampa,  FL, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms

This program is supported by educational grants from Caribou Biosciences, Inc., Kite, A Gilead Company, Legend Biotech, and Miltenyi Biomedicine. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
Hilton - Grand Ballroom AB

CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy represents a standard of care immunotherapy option across non-Hodgkin lymphoma (NHL), including in diffuse large B-cell and follicular lymphoma. Advances in manufacturing platforms and the development of next-generation constructs promise to provide additional options—including dual targeting, faster manufacturing, or in-vivo CAR-Ts that hold potential to expand access for patients who may not be able to undergo the complex delivery of traditional cell therapies. Collectively these developments are expanding the therapeutic footprint of CAR-T and accelerating the integration of cellular therapy in modern NHL management protocols.

PeerView has partnered with HealthTree Foundation for Non-Hodgkin Lymphoma to prepare this educational symposium featuring a panel of hematology-oncology experts. During this event, the faculty will use workshop-style discussions to offer practical guidance for operationalizing CAR-T within multidisciplinary workflows and care pathways while addressing the movement of CAR-T earlier in the treatment continuum and the emergence of potential next-generation cellular therapy options.

Chair:

Sairah Ahmed , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Speakers:

Sunita Dwivedy Nasta , MD
Hospital of the University of Pennsylvania
Philadelphia,  PA, United States

Nirav N. Shah , MD
Medical College of Wisconsin
Milwaukee,  WI, United States

Managing Company Contact

Grayson Baldy , PVI, PeerView Institute for Medical Education
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by GSK.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
Sheraton - Napoleon Ballroom CD

Presented by Neil Love and  Research To Practice, this 1.5-hour CME-accredited activity — offered to both in-person and virtual attendees — has been designed to address key questions regarding the use of bispecific antibodies and antibody-drug conjugates for patients with multiple myeloma (MM). Three clinical investigators will serve as the faculty, one of whom will moderate. Prior to the symposium, RTP will recruit 50 general medical oncologists/hematologists (GMOs) to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the use of bispecific antibodies and antibody-drug conjugates in MM. During the symposium, survey results highlighting areas of greatest interest will be presented. Each faculty member will then review relevant research findings, discuss current management approaches and provide perspectives on ongoing studies relevant to the topics prioritized by the GMOs who completed the survey. To promote audience engagement, attendees will be invited to submit questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Meletios A. Athanasios Dimopoulos , MD
National and Kapodistrian University of Athens
Athens,  Greece

Suzanne Trudel , MD
National and Kapodistrian University of Athens
Athens,  Greece

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know:  A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting

This program is supported by ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, and Bristol Myers Squibb.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
Sheraton - Napoleon Ballroom AB

Presented by Dr Neil Love and Research To Practice (RTP), this 2-hour CME-accredited activity — offered to both in-person and virtual attendees — has been designed to address many of the questions related to the use of novel agents for patients with non-Hodgkin lymphoma (NHL) for which learners want and need answers. Five clinical investigators with expertise in the disease will serve as the faculty, one of whom will moderate. Leading up to the symposium, RTP will recruit 50 general medical oncologists/hematologists (GMOs) to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the use of novel agents in NHL. During the symposium, selected survey results highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss their current management approaches and provide perspectives on ongoing studies relevant to the topics prioritized by the GMOs who completed the survey. To promote audience engagement, in-person and virtual attendees will be able to submit their own questions and clinical cases, a number of which will be incorporated by the program moderator into the faculty panel discussions throughout the program. In-person participants will engage via networked iPads provided in the meeting room, while virtual attendees will have the same functionality via the Zoom platform.

Speakers:

Paolo Fabrizio Caimi , MD, MBA
University Hospitals Seidman Cancer Center
Cleveland,  OH, United States

Mark Hoffman , MD
The University of Kansas Cancer Center
Kansas City,  MO, United States

Brad S Kahl , MD
Washington University School of Medicine
St Louis,  United States

Sonali Smith , MD
The University of Chicago
Chicago,  IL, United States

Managing Company Contact

Sylvia Eriksen , Research To Practice
Email: [email protected]

---

Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care

This program is supported by La Roche Ltd.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - Great Hall BC

Join this engaging, interactive symposium exploring the rapidly evolving landscape of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). Leading international experts will dive into topline clinical evidence across second- and third-line settings and frontline horizons, evaluating pivotal trial data in transplant-ineligible and high-risk populations.

Through real-world clinical case scenarios, the panel will debate treatment sequencing—weighing bispecifics against chimeric antigen receptor (CAR) T-cell therapy, individualizing care based on patient fitness and geographic access, and assessing impacts on T-cell fitness. Furthermore, faculty will address key practicalities for integrating bispecific therapies into community practice, from managing safety and treatment logistics to streamlining care coordination and patient pathways. Walk away with concrete solutions to optimize sequencing, safety, and care delivery across the DLBCL continuum.

Chair:

Wendy Osborne , MRCP, MRCPath
Newcastle University
Newcastle,  United Kingdom

Speakers:

Haifaa Abdulhaq , MD
University of California, San Francisco
Fresno,  CA, United States

Michael Dickinson , MD, MBBS, FRACP, FRCPA
Peter MacCallum Cancer Center and Royal Melbourne Hospital
Melbourne,  Australia

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Cases and Conversations™: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant

This program is supported by an educational grant from Omeros Corporation.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - La Nouvelle C

Allogeneic hematopoietic cell transplantation remains the only curative therapy for many patients with high-risk hematologic malignancies and severe non-malignant hematologic disorders, yet two of the highest-impact clinical decisions in the transplant pathway have been fundamentally reshaped within the past 12 months. The December 2025 approval of a nicotinamide-expanded cord blood platform for severe aplastic anemia, following its 2023 approval in hematologic malignancies, has expanded the donor hierarchy into non-malignant disease. The approval of narsoplimab, a first-in-class MASP-2 inhibitor for transplant-associated thrombotic microangiopathy, has introduced on-label therapy into a clinical space previously defined entirely by off-label management. This Cases and Conversations satellite symposium uses sequential patient cases and moderated faculty panel discussions to examine graft platform selection across malignant and non-malignant indications and the recognition, risk stratification, and mechanism-directed management of transplant-associated thrombotic microangiopathy across the post-transplant continuum.

Speakers:

Jeffrey Laurence , MD
Weill Cornell Medicine
New York,  NY, United States

Alessandro Rambaldi , MD
University of Milan
Milan,  Italy

Michelle L. Schoettler , MD
Emory University School of Medicine
Atlanta,  GA, United States

Managing Company Contact

Kelly McGregor , MJH Life Sciences
Email: [email protected]

---

Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis

This program is supported by Blueprint Medicines, a Sanofi company and Cogent Biosciences, Inc.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - Hall C

Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast.

Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum.

Chair:

Tracy I George , MD
University of Utah
Salt Lake City,  UT, United States

Speakers:

Hussein Ali Abbas , MD, PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX, United States

Lindsay Rein , MD
Duke University Health System
Durham,  NC, United States

Managing Company Contact

Carolyn Ciaramella , Medscape Live Meeting Services, LLC
Email: [email protected]

Registration for In-Person Program

Registration for Virtual Program

---

Medical Crossfire®: Frontline Decision-Making in CLL — Today's Choices, Tomorrow's Consequences

This program is supported by Eli Lilly and Company.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - La Nouvelle A-B

The frontline therapeutic landscape for chronic lymphocytic leukemia has shifted decisively from chemoimmunotherapy toward targeted oral agents, and clinicians now choose among continuous covalent and non-covalent BTK inhibitors, fixed-duration BCL-2 inhibitor combinations, and emerging MRD-guided strategies. Pivotal phase 3 readouts — AMPLIFY (acalabrutinib + venetoclax ± obinutuzumab), CLL17, BRUIN CLL-313/-314 (pirtobrutinib), CELESTIAL-TN (sonrotoclax + zanubrutinib), and MAJIC — have reshaped both the treatment armamentarium and the decision framework around fixed-duration vs continuous therapy. Real-world data show persistent gaps in molecular testing, treatment selection, and toxicity management. This Medical Crossfire® session uses focused didactic primers paired with moderated expert debate to examine the frontline decision points clinicians face every day, with attention to molecular testing, fixed-duration vs continuous therapy, MRD-guided approaches, and proactive AE management.

Chair:

Jennifer R. Brown , MD, PhD
Dana-Farber Cancer Institute
Boston,  MA, United States

Managing Company Contact

Kelly McGregor , Physicians' Education Resource, LLC
Email: [email protected]

---

Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia

This program is supported by Servier Pharmaceuticals, LLC.

Friday, December 11, 2026
7:00 p.m. - 10:00 p.m. Central time
MCCNO - 343-345

This symposium will address critical gaps in knowledge, competence, and clinical application among hem/onc clinicians managing patients with acute lymphoblastic leukemia, particularly adolescents and young adults. The activity is designed to support alignment with evolving evidence and guideline recommendations, with the ultimate goal of optimizing patient outcomes. The live symposium will employ an expert roundtable educational format in which a faculty panel will present evidence-based content, engage in interactive discussions, and provide practice insights to contextualize complex and data-rich information. Emphasis will be placed on real-world decision-making to help learners navigate the unique clinical and psychosocial considerations involved in treating this population. Embedded audience polling questions throughout the program will promote active engagement, reinforce clinical reasoning, and facilitate practical application of evidence-based strategies in patient care.

Chair:

Stephen P. Hunger , MD
Children's Hospital of Philadelphia
Philadelphia,  PA, United States

Speakers:

Seth E Karol , MD
St. Jude Children's Research Hospital
Memphis,  TN, United States

Marlise Rachael Luskin , MD
Dana-Farber Cancer Institute
Boston,  MA, United States

Managing Company Contact

Greg Maheu , Paradigm Medical Communications, LLC
Email: [email protected]

---